Targeted nucleic acid delivery to mitochondria

Current Gene Therapy

Volumn 9, Issue 6, 2009, Pages 475-486

  Vaidya, Bhuvaneshwar ^a   Mishra, Neeraj ^a   Dube, Devyani ^a   Tiwari, Shailja ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Mitochondria targeting; Mitochondrial DNA; Nucleic acid delivery

Indexed keywords

CLATHRIN; DRUG CARRIER; FOLIC ACID; LIPOSOME; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN;

CELL BASED GENE THERAPY; CYTOSOL; ENDOCYTOSIS; ENDOSOME; EUKARYOTIC CELL; GENE GUN; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; INTERNALIZATION; MITOCHONDRIAL GENETICS; MITOCHONDRIAL GENOME; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; DNA; DNA, MITOCHONDRIAL; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; MITOCHONDRIA; MOLECULAR SEQUENCE DATA; NUCLEIC ACIDS; OXIDATIVE PHOSPHORYLATION;

EID: 73449136874     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309790031102     Document Type: Review

References (109)

1. Paliwal R, Rai S, Vaidya B, et al. Cell-selective mitochondrial targeting: progress in mitochondrial medicine. Curr Drug Deliv 2007; 4: 211-24.
2. Szewczyk A, Wojtczak L. Mitochondria as a pharmacological target. Pharmacol Rev 2002; 54: 101-27.
3. Mukhopadhyay A, Weiner H. Delivery of drugs and macromolecules to mitochondria. Adv Drug Deliv Rev 2007; 59: 729-38.
4. Murphy MP, Smith RAJ. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev 2000; 41: 235-50.
5. Yamada Y, Harashima H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev 2008; 60: 1439-62.
6. DiMauro S. Mitochondrial myopathies. Curr Opin Rheumatol 2006; 18: 636-41.
7. Martin LJ. Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006; 65: 1103-10.
8. Sarzi E, Brown MD, Lebon S, et al. A novel recurrent mitochondrial DNA mutation in ND3 gene is associated with isolated complex I deficiency causing Leigh syndrome and dystonia. Am J Med Genet A 2007; 143: 33-41.
9. Kagawa Y, Inoki Y, Endo H. Gene therapy by mitochondrial transfer. Adv Drug Deliv Rev 2001; 49: 107-19.
10. Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet 2005; 6: 389-402.
11. Chinnery PF, Taylor RW, Diekert K, et al. Peptide nucleic acid delivery to human mitochondria. Gene Ther 1999; 6: 1919-28.
12. Gross NJ, Getz GS, Rabinowitz M. Apparent turnover of mitochondrial deoxyribonucleic acid and mitochondrial phospholipids in the tissues of the rat. J Biol Chem 1969; 244: 1552-62.
13. Lestienne P, Bataillé N. Mitochondrial DNA alterations and genetic diseases: a review. Biomed Pharmacother 1994; 48: 199-214.
14. Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988; 242: 1427-30.
15. Pulkes T, Hanna MG. Human mitochondrial DNA diseases. Adv Drug Deliv Rev 2001; 49: 27-43.
16. Newman NJ. Leber's hereditary optic neuropathy. New genetic considerations. Arch Neurol 1993; 50: 540-8.
17. Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46: 428-33.
18. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990; 348: 651-3.
19. Shoffner JM, Lott MT, Lezza AM, et al. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 1990; 61; 931-7.
20. Taniike M, Fukushima H, Yanagihara I. et al. Mitochondrial tRNA(Ile) mutation in fatal cardiomyopathy. Biochem Biophys Res Commun 1992; 186: 47-53.
21. Shanske S, Moraes CT, Lombes A. et al. Widespread tissue distribution of mitochondrial DNA deletions in Kearns-Sayre syndrome. Neurology 1990; 40: 24-8.
22. Otsuka M, Niijima K, Mizuno Y, et al. Marked decrease of mitochondrial DNA with multiple deletions in a patient with familial mitochondrial myopathy. Biochem Biophys Res Commun 1990; 167: 680-5.
23. Muratovska A, Lightowlers RN, Taylor RW, Wilce JA, Murphy MP. Targeting large molecules to mitochondria. Adv Drug Deliv Rev 2001; 49: 189-98.
24. Chowdhury EH, Akaike T. Bio-Functional Inorganic Materials: an attractive branch of gene-based nano-medicine delivery for 21st century. Curr Gene Ther 2005; 5: 669-76.
25. Schätzlein AG, Uchegbu IF. Non-viral vectors in gene delivery. Drug Deliv 2001; 1: 17-23.
26. Lechardeur D, Lukacs GL. Intracellular barriers to non-viral gene transfer. Curr Gene Ther 2002; 2: 1831-94
27. Langner M. The intracellular fate of non-viral DNA carriers. Cell Mol Biol Lett 2000; 5: 295-313.
28. Bulmus V. Biomembrane-active molecular switches as tools for intracellular drug delivery. Aust J Chem 2005; 58: 411-22.
29. Rawat A, Vaidya B, Khatri K, et al. Targeted intracellular delivery of therapeutics: an overview. Pharmazie 2007; 62: 643-58.
30. Belting M, Sandgren S, Wittrup A. Nuclear delivery of macromolecules: barrier and carriers. Adv Drug Deliv Rev 2005; 57: 505-27.
31. Lloyd JB. Lysosome membrane permeability: Implications for drug delivery. Adv Drug Deliv Rev 2000; 41: 189-200.
32. Mukherjee S, Ghosh RN, Maxfield FR. Endocytosis. Physiol Rev 1997; 77: 759-803.
33. Molema G, Meijer DKF. Targeting of drugs to various blood cell types using (neo-) glycoproteins, antibiotics and other protein carriers. Adv Drug Deliv Rev 1994; 14: 25-50.
34. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathway and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006; 58: 32-45.
35. Midoux P, Breuzard G, Gomez JP, Pichon C. Polymer-based gene delivery: a current review on the uptake and intracellular trafficking of polyplexes. Curr Gene Ther 2008; 8: 335-52.
36. Mousavi SA, Malerod L, Berg T, Kjeken R. Clathrin-dependent endocytosis. Biochem J 2004; 377: 1-16.
37. Hansen SH, Sandvig K, van Deurs B. The preendosomal compartment comprises distinct coated and noncoated endocytic vesicle populations. J Cell Biol 1991; 113: 731-41.
38. Takei K, Haucke V. Clathrin-mediated endocytosis: membrane factors pull the trigger. Trends Cell Biol 2001; 11: 385-91.
39. Harris J, Werling D, Hope JC, Taylor G, Howard CJ. Caveolae and caveolin in immune cells: distribution and functions. Trends Immunol 2002; 23: 158-64.
40. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature (Lond) 2003; 422: 37-44.
41. Panyam J, Labhasetwar, V. Targeting intracellular targets. Curr Drug Deliv 2004; 1: 1-13.
42. Hansen SH, Sandvig K, van Deurs B. Molecules internalized by clathrin-independent endocytosis are delivered to endosomes containing transferrin receptors. J Cell Biol 1993; 123: 89-97.
43. Rijnboutt S, Jansen G, Posthuma G, et al. Endocytosis of GPI-linked membrane folate receptor-alpha. J Cell Biol 1996; 132: 35-47.
44. Nakase I, Niwa M, Takeuchi T, et al. Cellular uptake of argininerich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 2004; 10: 1011-22.
45. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10: 310-15.
46. Kaplan IM, Wadia JS, Dowdy SF. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Rel 2005; 102: 247-53.
47. Zelphati O, Szoka FC, Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 1996; 93: 11493-98.
48. Montier T, Benvegnu T, Jaffrès P-A, Yaouanc J-J, Lehn P. Progress in cationic lipid-mediated gene transfection: a series of bioinspired lipids as an example. Curr Gene Ther 2008; 8: 296-312.
49. Lechardeur D, Sohn KJ, Haardt M, et al. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther 1999; 6: 482-97.
50. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Del Rev 2005; 57: 637-51.
51. Varga CM, Wickham TJ, Lauffenburger DA. Receptor-mediated targeting of gene delivery vectors: insights from molecular mechanisms for improved vehicle design. Biotechnol Bioeng 2000; 70: 593-605.
52. Fabre JW, Collins L. Synthetic peptides as non-viral DNA vectors. Curr Gene Ther 2006; 6:459-80.
53. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 2006; 8: 343-75.
54. Lewin M, Carlesso N, Tung CH, et al. TAT peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000; 18: 410-14.
55. Liu J, Zhang Q, Remsen EE, Wooley KL. Nanostructured materials designed for cell binding and transduction. Biomacromolecules 2001; 2: 362-8.
56. Dodd CH, Hsu HC, Chu WJ, et al. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J Immunol Methods 2001; 256: 89-105.
57. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors, Proc Natl Acad Sci USA 2001; 98: 8786-91.
58. Levchenko TS, Rammohan R, Volodina N, Torchilin VP. TAT peptide-mediated intracellular delivery of liposomes, Methods Enzymol 2003; 372: 339-49.
59. Xue FL, Chen JY, Guo J, et al. Enhancement of intracellular delivery of CdTe Quantum Dots (QDs) to living cells by Tat conjugation. J Fluoresc 2007; 17: 149-54.
60. Torchilin VP, Levchenko TS, Rammohan R, et al. Cell transfection in vitro and in vivo with non-toxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA 2003; 100: 1972-7.
61. Kashio A, Sakamoto T, Suzukawa K, et al. A protein derived from the fusion of TAT peptide and FNK, a Bcl-x(L) derivative, prevents cochlear hair cell death from aminoglycoside ototoxicity in vivo. J Neurosci Res 2007; 85: 1403-12.
62. Del Gaizo V, MacKenzie JA, Payne RM. Targeting proteins to mitochondria using TAT. Mol Genet Metab 2003; 80: 170-80.
63. Del Gaizo V, Payne RM. A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol Ther 2003; 7: 720-30.
64. Asoh S, Ohsawa I, Mori T, et al. Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci USA 2002; 99: 17107-12.
65. Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 1961; 191: 144-8.
66. Murphy MP. Slip and leak in mitochondrial oxidative phosphorylation. Biochim Biophys Acta 1989; 977: 123-41.
67. Azzone GF, Pietrobon D, Zoratti M. Determination of the proton electrochemical gradient across biological membranes. Curr Top Bioenergy 1984; 13: 1-77.
68. Burns RJ, Murphy MP. Labeling of mitochondrial proteins in living cells by the thiol probe thiobutyltriphenylphosphonium bromide. Arch Biochem Biophys 1997; 339: 33-9.
69. Rottenberg H. The measurement of membrane potential and deltapH in cells, organelles, and vesicles. Methods Enzymol 1979; 55: 547-69.
70. Chen LB. Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 1988; 4: 155-81.
71. Neupert W. Protein import into mitochondria. Annu Rev Biochem 1997; 66: 863-17.
72. Schatz GJ. The protein import system of mitochondria. J Biol Chem 1996; 271: 31763-66.
73. Pfanner N, Craig EA, Honlinger A. Mitochondrial preprotein translocase. Annu Rev Cell Dev Biol 1997; 13:25-51.
74. Pfanner N, Craig EA, Meijer M. The protein import machinery of the mitochondrial inner membrane. Trends Biochem Sci 1994; 19: 368-72.
75. Weissig V, Bodapati SV, D'Souza GGM, et al. Targeting of low-molecular weight drugs to mammalian mitochondria. Drug Des Rev 2004; 1: 15-28.
76. Favard C, Dean DS, Rols M-P. Electrotransfer as a non viral method of gene delivery. Curr Gene Ther 2007; 7:67-77.
77. Collombet JM, Wheeler VC, Vogel F, Coutelle C. Introduction of plasmid DNA into isolated mitochondria by electroporation. J Biol Chem 1997; 272: 5342-7.
78. Wheeler VC, Aitken M, Coutelle C. Modification of the mouse mitochondrial genome by insertion of an exogenous gene. Gene 1997; 198: 203-9.
79. Butow RA, Fox TD. Organelle transformation: shoot first, ask questions later. Trends Biochem Sci 1990; 15: 465-8.
80. Li S, Ma Z. Nonviral gene gherapy. Curr Gene Ther 2001; 1: 201-26.
81. Weissig V, Torchilin VP. Cationic bolasomes with delocalized charge centers as mitochondria-specific DNA delivery systems. Adv Drug Deliv Rev 2001; 49: 127-49.
82. Smith RAJ, Porteous CM, Coulter CV, et al. Selective targeting of an antioxidant to mitochondria. Eur J Biochem 1999; 263: 709-16.
83. Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells. J Biol Chem 2001; 276: 4588-96.
84. James AM, Cochemé HM, Smith RA, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem 2005; 280: 21295-312.
85. Smith RA, Porteous CM, Gane AM, Murphy MP. Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci USA 2003; 100: 5407-12.
86. Filipovska A, Kelso GF, Brown SE, Beer SM, Smith RA, Murphy MP. Synthesis and characterization of a triphenylphosphonium-conjugated peroxidase mimetic: Insights into the interaction of ebselen with mitochondria. J Biol Chem 2005; 280: 24113-26.
87. Ross MF, Da Ros T, Blaikie FH, et al. Accumulation of lipophilic dications by mitochondria and cells. Biochem J 2006; 400: 199-208.
88. Skulachev VP, Anisimov VN, Antonenko YN, et al. An attempt to prevent senescence: a mitochondrial approach. Biochim et Biophys Acta (BBA) - Bioenergetics 2009; 1787: 437-61.
89. Muratovska A, Lightowlers RN, Taylor RW, et al. Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease. Nucleic Acids Res 2001; 29: 1852-63.
90. Murphy MP. Targeting bioactive compounds to mitochondria. Trends Biotechnol 1997; 15: 326-30.
91. Verner K, Lemire BD. Tight folding of a passenger protein can interfere with the targeting function of a mitochondrial presequence. EMBO J 1989; 8: 1491-5.
92. Flierl A, Jackson C, Cottrell B, et al. Targeted delivery of DNA to the mitochondrial compartment via import sequence conjugated peptide nucleic acid. Mol Ther 2003; 7: 550-7.
93. Seibel P, Trappe J, Villani G, et al. Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases. Nucleic Acids Res 1995; 23: 10-17.
94. Vestweber D, Schatz G. DNA-protein conjugates can enter mitochondria via the protein import pathway. Nature 1989; 338: 170-2.
95. Shokolenko IN, Alexeyev MF, LeDoux SP, Wilson GL. TAT-mediated protein transduction and targeted delivery of fusion proteins into mitochondria of breast cancer cells. DNA Repair (Amst) 2005; 4: 511-8.
96. Choi JS, Choi MJ, Ko KS, et al. Low molecular weight polyethylenimine-mitochondrial leader peptide conjugate for DNA delivery to mitochondria. Bull Korean Chem Soc 2006; 27: 1335-40.
97. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995; 270:18997-9007.
98. Chin DJ, Green GA, Zon G, Szoka FC, Jr, Straubinger RM. Rapid nuclear accumulation of injected oligodeoxyribonucleotides. N Biol 1990; 2:1091-100.
99. Xu Y, Szoka FC. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996; 35: 5616-23.
100. Weissig V, Lasch J, Erdos G, et al. DQAsomes: a novel potential drug and gene delivery system made from Dequalinium. Pharm Res 1998; 15: 334-7.
101. Weissig V, Lizano C, Torchilin VP. Selective DNA release from DQAsome/DNA complexes at mitochondria-like membranes. Drug Deliv 2000; 7: 1-5.
102. Weissig V, D'Souza GG, Torchilin VP. DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. J Control Rel 2001; 75: 401-8.
103. D'Souza GG, Rammohan R, Cheng SM, Torchilin VP, Weissig V. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Rel 2003; 92:189-97.
104. Lasch J, Meye A, Taubert H, et al. Dequalinium vesicles form stable complexes with plasmid DNA which are protected from DNase attack. Biol Chem 1999; 380: 647-52.
105. D'Souza GG, Boddapati SV, Weissig V. Mitochondrial leader sequence-plasmid DNA conjugates delivered into mammalian cells by DQAsomes co-localize with mitochondria. Mitochondrion 2005; 5: 352-8.
106. Felgner PL , Gadek TR , Holm M , et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-7.
107. Gao X, Kim KS, Liu D. Nonviral gene delivery: What we know and what is next. AAPS J 2007; 9: E92-104.
108. Weissig V. Targeted drug delivery to mammalian mitochondria in living cells. Expert Opin Drug Deliv 2005; 2: 89-102.
109. Vaidya B, Paliwal R, Rai S, et al. Cell-selective mitochondrial targeting: A new approach for cancer therapy. Cancer Ther 2009; 7(A): 141-8.